Articles tagged with Immunotherapy
The ECOG-ACRIN Cancer Research Group has opened a new treatment arm in the NCI-MATCH trial for patients with DNA mismatch repair deficiency and LAG-3 expression. The trial is evaluating two immunotherapy combinations: relatlimab plus nivolumab and dabrafenib plus trametinib, both targeting BRAF mutations.
A new study reveals that intra-tumoral injections of a plant virus-based immunotherapy could lead to groundbreaking therapy for both canine and human inflammatory breast cancer patients. The treatment generated potent local and systemic anti-tumor immune responses, improving quality of life and survival in treated dogs.
Researchers developed a novel genetic barcode system to mark cancer cells with different gene modifications and image their characteristics. The Perturb-map platform identified specific genes controlling lung tumor growth, immune composition, and response to immunotherapy, offering new approaches for targeting anti-cancer drugs.
Researchers have discovered a new treatment that blocks inflammation in pancreatic cancer, making it sensitive to chemotherapy and immunotherapy. The therapy more than doubled survival rates in mice with pancreatic cancer, providing promising results for future human trials.
Researchers found an association between a specific HLA-DPB1 gene variant and poor response to sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. The study suggests that genotyping the HLA-DPB1 gene could help predict patient responsiveness to SLIT.
Researchers found that patients with stage III melanoma who received immunotherapy alone had better rates of distant metastasis-free survival compared to those who underwent completion lymph node dissection. The study suggests that de-escalation of unnecessary therapies, such as CLND, may improve patient outcomes and reduce complications.
Researchers developed a microneedle treatment that increased desensitization rates to peanut allergy in mice, outperforming existing immunotherapy methods. The novel approach achieved significant results using lower doses of allergen, offering new hope for millions suffering from peanut allergy.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
Researchers developed a novel scaffold to grow breast tumors with reduced immune variability, enabling more accurate immunotherapy drug testing. The new model replicates treatment-resistant breast cancer microenvironments and predicts patient responses to therapy.
A University of Cincinnati clinical trial showed promising results for patients with intermediate risk head and neck cancer when an immunotherapy drug, pembrolizumab, was added to standard treatment regimens. The study found improved one-year disease-free survival rates compared to historical controls.
Researchers at Lund University have developed a new precision medicine technology, TS-MAP, to identify and target cancer cell surface proteins. The method provides a direct analysis of all accessible cell surface tumour antigens in tumour tissue from patients.
A recent study found that women have a 34% higher risk of severe toxicity than men in cancer treatment, with higher risks for immunotherapy and targeted therapies. The analysis of over 20,000 patients from more than 200 clinical trials supports the idea that sex may independently modulate drug toxicity.
A recent study from Lund University found a previously unknown metabolic switch that regulates blood cell formation, enabling the directed production of natural killer cells for anti-cancer treatment. This discovery has significant implications for immunotherapy and cancer treatment.
Researchers have identified an antibody drug that significantly improves survival rates in pet dogs with advanced prostate cancer. By targeting regulatory T cells, the treatment may offer a new hope for patients with this devastating disease.
Two new treatments have been found to induce peanut allergy remission in children, with about half achieving remission and experiencing significant improvements in quality of life. The combination treatment and oral immunotherapy alone were both highly effective, providing substantial benefits for children's health and well-being.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers found sublingual immunotherapy with house dust mite extract to be effective in reducing signs and symptoms of atopic dermatitis. The treatment, administered over 18 months, resulted in significant improvements in pruritus and lesions, with rare side effects.
Researchers have identified a germline biomarker signature that can predict serious side effects in up to 3 in 10 patients undergoing anti-PD1/PDL1 therapy. The findings represent an important step toward personalizing checkpoint therapy, potentially improving patient outcomes and reducing harm.
Researchers at Gladstone Institutes and UC San Francisco have developed a CRISPR activation method that allows them to activate genes in human immune cells, revealing key regulators of cytokine production. This breakthrough accelerates immunotherapy research and may lead to more powerful cancer treatments.
A Brazilian berry has been found to enhance the effectiveness of a popular cancer treatment by modifying the gut microbiome. Researchers discovered that castalagin, a polyphenol from the camu-camu fruit, improves immunotherapy response in mice with resistant cancers.
Researchers used a patient's own immune cells to target unique mutations in tumor DNA, leading to measurable tumor shrinkage in 67% of patients with metastatic breast cancer. The approach has potential as a personalized treatment for hormone receptor-positive breast cancers.
Researchers have discovered a new method to predict heart attacks by analyzing the gene expression of foamy macrophages, revealing a person's cardiovascular health. The study found that foamy cells can be both beneficial and detrimental depending on their behavior in individuals with certain conditions.
Researchers at Massachusetts General Hospital developed a safe and effective strategy to treat glioblastoma using short bursts of radiation therapy and nanoparticle-based immunotherapy. The combined approach suppresses tumor growth, induces anti-tumor immunity, and prolongs survival in animal models.
Researchers found that macrophages feed on lactic acid produced by cancer cells, paralyzing killer immune cells and weakening tumour immunity. This discovery highlights the need to curb lactic acid production in tumours to improve immunotherapy outcomes.
A clinical trial found that peanut oral immunotherapy desensitized most highly allergic children and induced remission in one-fifth. Younger children and those with lower levels of peanut-specific antibodies were more likely to achieve remission, with 71% of 1-year-olds experiencing remission.
A randomised controlled trial found that most young children treated with peanut immunotherapy achieved desensitisation after two and a half years of treatment, while one in five remained in remission. Younger children under one year old were more likely to achieve remission, suggesting early interventions may provide better outcomes.
A new bilateral tumor model was demonstrated to be useful for investigating the relationship between T-cell repertoire and cancer immunotherapy's therapeutic effects. The study found that T-cell profiles of both tumors were almost identical, indicating a similar anti-tumor response in a single mouse.
A team of scientists at the University of Missouri used small wearable sensors to gather data on how people with a traumatic hand amputation use a prosthesis versus a transplanted hand. The study found that hand transplant recipients exhibit a more balanced pattern of limb use, while prosthesis users rely heavily on their prosthetic hand.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
A new study found that translocation renal cell carcinoma (tRCC) is characterized by genetic alterations except for the gene fusion from which it gets its name. The research suggests that tRCCs may be responsive to treatment with immune checkpoint inhibitors, providing a potential roadmap for clinical action.
Researchers at UCSF identify unique immune microenvironments in different types of cancer, paving the way for personalized immunotherapies. The study categorizes tumors into 12 groups based on their immune profile, suggesting that some cancers share similar characteristics despite being from different types.
The combination of relatlimab and nivolumab doubled progression-free survival benefit compared to nivolumab alone, with significant benefits across pre-specified subgroups. The treatment was associated with a lower risk of disease progression or death.
A high-fiber diet has been shown to improve the response of melanoma patients to immunotherapy by influencing the gut microbiome. Patients who consumed at least 20 grams of dietary fiber per day lived longer without their cancer progressing, compared to those who consumed less fiber.
Patients with sufficient fiber intake had improved progression-free survival and response to immunotherapy in melanoma. A high-fiber diet was associated with slower tumor growth and increased CD4+ T cells in pre-clinical models, supporting the potential benefits of dietary interventions on cancer treatment outcomes.
Scientists have identified the transcription factor Blimp1 as a new critical regulator of tumor-infiltrating regulatory T cells. Disrupting Blimp1 in these cells remodels the tumor microenvironment and augments the response to immunotherapy, promoting improved tumor control and anti-tumor immunity.
A new treatment combination of dasatinib, blinatumomab, and prednisone has shown promise in treating older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. The trial achieved a three-year DFS rate of 80 percent and an overall survival rate of 85 percent for enrolled patients.
A case study published in Nature Medicine reports a patient experiencing progressive neurological features resembling Parkinson's disease after CAR-T cell therapy, suggesting potential neurotoxicity. The study highlights the importance of monitoring for neurotoxicity in patients receiving BCMA-targeted CAR-T therapies.
Scientists from German Cancer Research Center show that blocking a cytokine slows down the immune system and exhausts T cells, leading to a more severe course of leukemia. The study suggests that a moderate activation of immune cells may be key to success in cancer immunotherapies.
Researchers at University of California San Diego found a way to boost innate immunity in liver cancer, making tumors highly responsive to immunotherapy. The combination of anti-PD-L1 antibody and polyIC molecule showed remarkable synergistic effects in liver tumor inhibition.
A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.
Researchers found that second-generation antihistamines block histamine binding to HRH1, improving cytotoxic T cell activation and reducing resistance to immunotherapy. High plasma histamine levels in patients were correlated with worse responses to anti-PD-1 immunotherapy.
Researchers at Children's National Hospital have successfully developed a personalized T cell immunotherapy that targets and kills unique proteins in individual tumor cells. This approach, combining genetic sequencing and protein identification, offers a promising treatment option for children with hard-to-treat brain tumors.
Gastric cancer is the sixth most common cancer worldwide, with 1.09 million new cases in 2020. Recent research offers hope for improved treatment options, making it a critical area of focus for medical oncologists like Dr. Mohamad Sonbol.
Researchers have developed an assay that uses specific immune-biomarkers to monitor patient survival chances and effectiveness of ovarian cancer treatments. The 'sFIS' assay will enable targeted therapy for each patient, improving treatment outcomes.
Researchers produce large quantities of powerful cancer-fighting iNKT cells using stem cell engineering and organoid technology, offering a potential solution for mass-producing an off-the-shelf immune cell therapy. The therapy, which uses hematopoietic stem cell-engineered iNKT cells, has been shown to be effective in killing multiple...
Patients with advanced renal cell carcinoma treated with checkpoint inhibitor combination nivolumab plus ipilimumab experienced longer treatment-free survival compared to those receiving targeted therapy sunitinib. The analysis revealed significant differences in how patients spent their overall survival time between the two treatments.
A Phase II study shows that combination treatment with nivolumab and ipilimumab improves overall survival in patients with asymptomatic melanoma brain metastases, with an overall survival rate of 71.9% at three years. The treatment demonstrates durable responses, even in symptomatic patients.
A nationwide study published in JAMA Oncology found that immunotherapy use among trial-ineligible solid-tumor cancer patients increased significantly between 2014 and 2019, yet no survival benefit was observed. Researchers emphasize cautious use of immunotherapies for this population due to potential early harm.
Researchers developed a mathematical model that can predict the effectiveness of immunotherapy treatment for individual patients based on standard clinical measures. The model showed high sensitivity in predicting treatment response within two months, with minimal false-negative results.
A phase 2 clinical trial shows durvalumab immunotherapy combined with standard chemotherapy significantly improved overall survival for patients with previously untreated malignant pleural mesothlioma. The study's findings provide insights into patient selection methods for this novel chemo-immunotherapy regimen.
Researchers discovered a new biomarker, inactive AMPK (lo-P-AMPK), that may predict immune evasion in lung cancer. The finding could enable better personalized care for lung cancer patients by identifying those most likely to benefit from immunotherapies.
Researchers at Children's Hospital of Philadelphia have developed a novel therapy that targets proteins essential for tumor growth and survival. Using a multi-omics approach, they identified peptides unique to neuroblastoma tumors, which are then targeted by peptide-centric chimeric antigen receptors (PC-CARs).
A new machine learning model developed by Timothy Chan accurately predicts whether immune checkpoint blockade will be effective in patients with various cancers. The tool assesses multiple patient-specific factors, including tumor mutational burden and chemotherapy history, to predict response and survival outcomes.
A team of researchers at George Washington University has identified DDR1 as a key molecule that prevents immune cells from entering and killing breast tumor cells. Deactivating this molecule allows immune cells to infiltrate the tumor and kill cancer cells, opening up new avenues for therapeutic agents.
Researchers are developing a transformative technology called Multiscale Intelligent Convergence (MusIC) to map the complexity of T cells and identify attributes essential for patient benefit. The goal is to create more reliable biomanufacturing of T cell infusion products and engineering potent immune cells.
Researchers from MUSC Hollings Cancer Center, UCLA Jonsson Comprehensive Cancer Center, and Winship Cancer Institute discovered that pre-surgical anti-PD-1 immunotherapy is safe and effective for OCSCC patients. The studies identified potential molecular biomarkers in blood and tumors to predict treatment response.
Researchers found immune cell patterns within tumours that can predict if patients with kidney cancer will respond to immunotherapy. The study identified a specific 'clonal' T cell receptor pattern linked to a greater chance of positive immunotherapy response.
Researchers at the University of Alabama at Birmingham have developed a method to identify non-responding tumors using hypoxia imaging, which shows promise for improving response rates. Investigational new drug evofosfamide was found beneficial in treating hypoxic tumors with immunotherapy.
Scientists at the University of Cambridge have found that T cell mitochondria regulate the refuelling of toxic weapons, enabling killer T cells to stay healthy and keep killing. This discovery sheds light on how these immune system assassins are able to sustain their deadly missions.
Researchers at Johns Hopkins University have developed a non-invasive optical probe to understand the complex changes in tumors after immunotherapy. Using Raman spectroscopy and machine learning, they identified key features that indicate how tumors respond to treatment, showing promising results for predicting patient response.